JPH11511962A - クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子 - Google Patents

クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子

Info

Publication number
JPH11511962A
JPH11511962A JP9501337A JP50133797A JPH11511962A JP H11511962 A JPH11511962 A JP H11511962A JP 9501337 A JP9501337 A JP 9501337A JP 50133797 A JP50133797 A JP 50133797A JP H11511962 A JPH11511962 A JP H11511962A
Authority
JP
Japan
Prior art keywords
protein
cloned
serum
cancer
macrophage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP9501337A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11511962A5 (enExample
Inventor
信人 山本
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/478,121 external-priority patent/US5620846A/en
Application filed by Individual filed Critical Individual
Publication of JPH11511962A publication Critical patent/JPH11511962A/ja
Publication of JPH11511962A5 publication Critical patent/JPH11511962A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01049—Alpha-N-acetylgalactosaminidase (3.2.1.49)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—HIV or HTLV
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/811—Test for named disease, body condition or organ function
    • Y10S436/813—Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
JP9501337A 1995-06-07 1996-06-05 クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子 Ceased JPH11511962A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/478,121 1995-06-07
US08/478,121 US5620846A (en) 1995-06-07 1995-06-07 Diagnostic and prognostic indices for cancer and aids
US08/618,485 US6410269B1 (en) 1995-06-07 1996-03-19 Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
US08/618,485 1996-03-19
PCT/US1996/008867 WO1996040903A1 (en) 1995-06-07 1996-06-05 Macrophage activating factors derived from cloned vitamin d binding protein

Publications (2)

Publication Number Publication Date
JPH11511962A true JPH11511962A (ja) 1999-10-19
JPH11511962A5 JPH11511962A5 (enExample) 2004-07-22

Family

ID=27045792

Family Applications (1)

Application Number Title Priority Date Filing Date
JP9501337A Ceased JPH11511962A (ja) 1995-06-07 1996-06-05 クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子

Country Status (12)

Country Link
US (3) US6410269B1 (enExample)
EP (3) EP0837932B1 (enExample)
JP (1) JPH11511962A (enExample)
CN (2) CN1510147A (enExample)
AT (1) ATE307885T1 (enExample)
AU (1) AU6253596A (enExample)
BR (1) BR9609072A (enExample)
CA (1) CA2223940A1 (enExample)
DE (2) DE69635346D1 (enExample)
ES (1) ES2252756T3 (enExample)
NO (1) NO323155B1 (enExample)
WO (1) WO1996040903A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532682A (ja) * 2000-05-09 2003-11-05 チルドレンズ メディカル センター コーポレーション 血管新生の治療のための方法および組成物
WO2012029954A1 (ja) 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
JP2016505043A (ja) * 2013-01-18 2016-02-18 クライン，エリス 免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
WO2022124331A1 (ja) 2020-12-08 2022-06-16 再生ファーマ株式会社 マクロファージ活性化剤

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5985545A (en) * 1996-03-19 1999-11-16 Yamamoto; Nobuto Diagnostic and prognostic ELISA assays of serum α-N-acetylgalactosaminidase for AIDS
US20050009120A1 (en) * 2000-09-07 2005-01-13 The Brigham And Women's Hospital, Inc. Methods of detecting ovarian cancer based on osteopontin
US6846642B2 (en) * 2000-09-07 2005-01-25 The Brigham And Women's Hospital, Inc. Methods of detecting cancer based on prostasin
EP1347953A2 (en) * 2000-11-09 2003-10-01 Northeastern Ohio Universities College of Medicine Agents and methods for promoting bone growth
US20020164664A1 (en) * 2000-11-30 2002-11-07 Matritech, Inc. Detection and treatment of prostate cancer
US7112408B2 (en) * 2001-06-08 2006-09-26 The Brigham And Women's Hospital, Inc. Detection of ovarian cancer based upon alpha-haptoglobin levels
US6806355B2 (en) 2001-08-14 2004-10-19 Statens Serum Institut Purification process for large scale production of Gc-globulin, the Gc-globulin produced hereby, a use of Gc.globulin and a Gc-globulin medicinal product
US7288383B2 (en) * 2003-01-15 2007-10-30 The Brigham And Women's Hospital, Inc. Eosinophil-derived neurotoxin as a marker for ovarian cancer
WO2005087793A2 (en) * 2004-02-05 2005-09-22 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US20050186577A1 (en) * 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2006063028A2 (en) * 2004-12-07 2006-06-15 The Arizona Board Of Regents, A Body Corporate Acting On Behalf Of Arizona State University Immunostimulatory compositions and uses thereof
US8460697B2 (en) 2006-12-13 2013-06-11 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US8496942B2 (en) 2006-12-13 2013-07-30 Susavion Biosciences, Inc. Therapeutic peptides and uses thereof
US7811995B2 (en) 2006-12-13 2010-10-12 Susavion Biosciences, Inc. Therapeutic and diagnostic peptides
USRE46425E1 (en) 2006-12-13 2017-06-06 Susavion Biosciences, Inc. Pro-angiogenic peptides and uses thereof
US7838497B2 (en) 2006-12-13 2010-11-23 Susavion Biosciences, Inc. Pro-angiogenic peptides
US20110123591A1 (en) * 2009-08-22 2011-05-26 Charles Knezevich Tumoricidal, bactericidal, or viricidal macrophage activation
EP2694088B1 (en) * 2011-04-07 2017-06-07 Efranat Ltd. Macrophage activating factor for pharmaceutical compositions
EP2561879A1 (en) 2011-08-23 2013-02-27 Protea Biopharma N.V. Macrophage activating factor for use in the treatment of chronic fatigue syndrome (CFS) and CFS-related diseases and disorders
WO2013130953A2 (en) * 2012-03-01 2013-09-06 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
EP2687264A1 (en) 2012-07-17 2014-01-22 Protea Biopharma N.V. Macrophage Activating Factor for treatment of endometriosis
CN105530950A (zh) * 2013-06-09 2016-04-27 艾弗兰纳特有限公司 包含Gc-巨噬细胞活化因子的组合物及其用途
AT518622A1 (de) * 2016-04-21 2017-11-15 Hg Pharma Gmbh Dimerer Komplex aus selektiv deglycosyliertem Vitamin D bindenden Protein (GcMAF) und Cholecalciferol (Calciol) und Verfahren zu dessen Herstellung
CN118325844B (zh) * 2023-09-07 2025-01-03 武汉奥科博泰生物科技有限公司 识别N-乙酰-β-D-氨基葡萄糖苷酶的单克隆抗体及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5177001A (en) 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5326749A (en) 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5516657A (en) * 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5652352A (en) * 1994-03-31 1997-07-29 Amgen Inc. Afamin: a human serum albumin-like gene

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003532682A (ja) * 2000-05-09 2003-11-05 チルドレンズ メディカル センター コーポレーション 血管新生の治療のための方法および組成物
WO2012029954A1 (ja) 2010-09-03 2012-03-08 国立大学法人徳島大学 新規Ｇｃグロブリンガラクトース脱糖体の製造方法
JP2016505043A (ja) * 2013-01-18 2016-02-18 クライン，エリス 免疫プログラミングおよび癌の治療のための選択的グリコシダーゼレジメン
WO2019117295A1 (ja) * 2017-12-15 2019-06-20 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
JPWO2019117295A1 (ja) * 2017-12-15 2020-04-16 公益財団法人神戸医療産業都市推進機構 活性型ＧｃＭＡＦの製造方法
US12312380B2 (en) 2017-12-15 2025-05-27 Foundation For Biomedical Research And Innovation At Kobe Method for producing active GcMAF
WO2022124331A1 (ja) 2020-12-08 2022-06-16 再生ファーマ株式会社 マクロファージ活性化剤

Also Published As

Publication number Publication date
EP1443112A3 (en) 2004-11-03
EP1340815A3 (en) 2003-09-17
CA2223940A1 (en) 1996-12-19
AU6253596A (en) 1996-12-30
DE69635346T2 (de) 2006-07-27
ATE307885T1 (de) 2005-11-15
US20020055140A1 (en) 2002-05-09
EP0837932A4 (en) 2001-02-28
WO1996040903A1 (en) 1996-12-19
CN1510147A (zh) 2004-07-07
EP0837932B1 (en) 2005-10-26
CN1191567A (zh) 1998-08-26
NO975771D0 (no) 1997-12-08
BR9609072A (pt) 2000-10-24
DE69635346D1 (de) 2005-12-01
ES2252756T3 (es) 2006-05-16
NO975771L (no) 1998-01-30
DE69635346T4 (de) 2007-11-08
EP1443112A2 (en) 2004-08-04
EP1340815A2 (en) 2003-09-03
CN1174097C (zh) 2004-11-03
US6410269B1 (en) 2002-06-25
EP0837932A1 (en) 1998-04-29
NO323155B1 (no) 2007-01-08
US5712104A (en) 1998-01-27

Similar Documents

Publication Publication Date Title
JPH11511962A (ja) クローン化したビタミンｄ結合タンパク質由来の大食細胞活性化因子
Peissel et al. Comparative distribution of the alpha 1 (IV), alpha 5 (IV), and alpha 6 (IV) collagen chains in normal human adult and fetal tissues and in kidneys from X-linked Alport syndrome patients.
BE1004201A5 (fr) L'amphireguline: une nouvelle glycoproteine bifonctionnelle modulatrice de la croissance.
CN102037359A (zh) 吞噬细胞的功能评价方法
Friedmann et al. Products of vasopressin gene expression in small-cell carcinoma of the lung
US10040829B2 (en) Methods for producing peptides including HERV-W envelope motifs and for producing antibodies specific for the peptides
JPH03195496A (ja) 成長因子
JPH10509037A (ja) 機能不全プロテアーゼ形成によるタンパク質分解活性の抑制
RU2198218C9 (ru) СПОСОБ КЛОНИРОВАНИЯ СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (БЕЛКА Gc), СПОСОБ ПОЛУЧЕНИЯ КЛОНИРОВАННОГО ФАКТОРА АКТИВАЦИИ МАКРОФАГОВ, ФАКТОР АКТИВАЦИИ МАКРОФАГОВ (ВАРИАНТЫ), АДЪЮВАНТ (ВАРИАНТЫ), КЛОНИРОВАННЫЙ СВЯЗЫВАЮЩИЙ ВИТАМИН D3 БЕЛОК (Gc-БЕЛОК), КЛОНИРОВАННЫЙ ДОМЕН III СВЯЗЫВАЮЩЕГО ВИТАМИН D3 БЕЛКА (ВАРИАНТЫ)
CN119409833A (zh) 一种抗ceacam5和ceacam6双靶向抗体及其应用
da Silva et al. Cell adhesion in transformed D. discoideum cells: expression of gp80 and its biochemical characterization
AU766098B2 (en) Thrombospondin-2 and uses thereof
US6503513B2 (en) Diagnostics and therapy of diseases associated with HHV-8 infections
Das et al. High-level expression of biologically active human prolactin from recombinant baculovirus in insect cells
US20060014143A1 (en) Preparation of potent macrophage activating factors derived from cloned vitamin D binding protein and its domain and their therapeutic usage for cancer, HIV-infection and osteopetrosis
JPH02427A (ja) ｃ−ｍｙｂタンパク質のエピトープを認識するモノクローナル抗体、および該抗体を産生するハイブリドーマセルライン
JPH02203795A (ja) 抗ヒト組織因子モノクローナル抗体
US6149945A (en) Human fibroblast diffusable factors
WO1991009969A1 (fr) Nouvel anticorps monoclonal antihumain de thrombomoduline et diagnostic de troubles endotheliaux par immuno-analyse enzymatique
JP2002500195A (ja) 自己免疫疾患を治療するためのフィラグリン由来シトルリンペプチドの使用
EP0275278A1 (en) Peptide fragments of organ-specific neoantigens
CA2152595A1 (en) Purified human chondrocalcin, process for producing the same, and utilization thereof
JPWO1995011920A1 (ja) 精製ヒトコンドロカルシン、その製造方法およびその利用
JPWO1995014231A1 (ja) 坑リン脂質抗体の測定法及びキット
JPH02284060A (ja) 成人ｔ細胞白血病ウイルス感染診断薬

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20060829

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20061128

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20070122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20070911

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20071127

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20080121

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20080508

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080617